ERKi |
ERKi : Inhibitor of MAPK1, MAPK3
Probe Summary
Selectivity
Potency
In Vivo
Control Compounds
Chemical Information
References
Vendors
Download
Probe Summary
| Targets | Biochemical/Biophysical Potency | Cellular Potency |
|---|---|---|
| MAPK1 |
|
|
| MAPK3 |
|
Inhibitor
1-5 µM may be more suitable in some cell lines
1 uM
Selectivity
In Vitro Selectivity Assessment
Selectivity Assessment Description:
Selectivity within target family: Invitrogen kinase panel. Closest off targets: GSK3A = 0.21 µM, SGK ...
In Cell Selectivity Assessment
Selectivity Assessment Description:
NanoBRET results: GSK3A, SGK1, GSK3B, GRK2 and TBK1 (IC50 > 20µM)
Potency Cellular
In Vitro
MAPK1
Mode of Action: Inhibitor
Structure-Activity-Relationship data available? No
DOI Reference: 10.7554/eLife.34311
MAPK3
Mode of Action: Inhibitor
Structure-Activity-Relationship data available? No
DOI Reference: 10.7554/eLife.34311
In Vivo Validations
Rat
Dose: 1 mg/Kg PO, 0.5 mg/Kg IV
Route of delivery:
Oral, Intravenous
Plasma half life:
0.4 h
Systemic clearance:
217 mL/min/kg
Fb :
84%
Bioavailability:
13%
Volume of Distribution at Steady-State:
5.7 L/Kg
DOI Reference: 10.7554/eLife.34311
Dog
Dose: 0.5 mg/Kg PO, 0.25 mg/Kg IV
Route of delivery:
Oral, Intravenous
Plasma half life:
2.1 h
Systemic clearance:
89 mL/min/kg
Fb :
87%
Bioavailability:
78%
Volume of Distribution at Steady-State:
15.2 L/Kg
DOI Reference: 10.7554/eLife.34311
Negative Control Compounds
ERKi-NC
Notes: The negative control is 1000-fold less potent biochemically and shows no activity in cells @ 10µM; GPCR scan shows weak off-target activity for HTR2B (pKi = 6.27).
Chemical Information
| Molecular Formula | C16H17N5O2 |
| SMILEs | C[C@@H](NC(=O)Nc1cc2[nH]ncc2c(CO)n1)c1ccccc1 |
| InChI | InChI=1S/C16H17N5O2/c1-10(11-5-3-2-4-6-11)18-16(23)20-15-7-13-12(8-17-21-13)14(9-22)19-15/h2-8,10,22H,9H2,1H3,(H,17,21)(H2,18,19,20,23)/t10-/m1/s1 |
| Molecular weight | 311.14 Da |
| AlogP | 2.3329000000000004 |
| HBond acceptors | 7 |
| HBond donors | 4 |
| Atoms | 40 |